30 research outputs found
Clinical profiles and risk factors for outcomes in older patients with cervical and trochanteric hip fracture: similarities and differences
Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass
Urban versus rural differences in the occurrence of hip fractures in Japan’s Kyoto prefecture during 2008–2010: a comparison of femoral neck and trochanteric fractures
Osteoporosis and the global competition for health care resources
Global aging superimposed on existing infectious diseases and trauma will aggravate competition for health care resources to diagnose and treat osteoporosis. Efforts to implement public health measures are needed, but the targeted approach to assessment and treatment of high-risk individuals must also be refined
Radioimmunologische Bestimmungen von menschlichem Wachstumshormon (STH) im Serum von 62 Patienten mit einer Akromegalie
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
OBJECTIVE: The aim of this study was to report the effects of denosumab on radius
cortical and trabecular bone density, mass, and strength, and wrist fracture
incidence in the FREEDOM (Fracture REduction Evaluation of Denosumab in
Osteoporosis every 6 Months) study.
METHODS: In the FREEDOM study, postmenopausal women with osteoporosis (N = 7,808)
received placebo or 60 mg of denosumab every 6 months for 36 months. Radius bone
mineral density (BMD), bone mineral content, and strength (polar moment of
inertia) were evaluated in two prespecified substudies using dual-energy x-ray
absorptiometry (placebo, n = 209; denosumab, n = 232) or quantitative CT
(placebo, n = 48; denosumab, n = 62). Prespecified analysis assessed wrist
fracture incidence in all FREEDOM participants (placebo, N = 3,906; denosumab, N
= 3,902), and post hoc subgroup analyses evaluated those with higher fracture
risk (baseline femoral neck T-score ?-2.5; placebo, N = 1,406; denosumab, N =
1,384).
RESULTS: Denosumab significantly increased areal BMD (assessed by dual-energy
x-ray absorptiometry) and volumetric BMD, bone mineral content, and polar moment
of inertia (assessed by quantitative CT), compared with placebo, in radius
cortical and trabecular bone at all time points evaluated (all P < 0.05). Wrist
fracture incidence was 2.9% for placebo and 2.5% for denosumab (relative risk
reduction, 16%; P = 0.21) on month 36. Participants with a femoral neck T-score
of -2.5 or lower were at increased risk for wrist fracture, and denosumab
significantly reduced wrist fracture incidence compared with placebo (placebo,
4.0%; denosumab, 2.4%; relative risk reduction, 40%; absolute risk reduction,
1.6%; P = 0.03).
CONCLUSIONS: Denosumab significantly improves radius bone density, mass, and
strength compared with placebo. In higher-risk women, denosumab significantly
reduces wrist fracture ris
Incidence of hip fracture in southeastern Norway: A study of 1,730 cervical and trochanteric fractures
The incidence of hip fracture has been studied extensively, but there is still some doubt whether the age-specific incidence is increasing. The proportion of trochanteric fractures has varied and has also been said to be increasing. We studied data on 1,730 prospectively registered cases from 1998–2003 and computed age- and gender-specific incidence rates for intracapsular and trochanteric fractures. The incidence of hip fracture for women over 50 years was 1,263 and for men 452 per 100,000. The proportion of trochanteric fractures was 38% for women and 41% for men. There was no significant difference in the proportion of trochanteric fractures either between or within the genders, and the proportion did not exceed 50% in any age group. These findings confirm the high incidence of hip fracture in Norway but do not indicate any increase. The proportion of trochanteric fractures also seems to be stable